$CORT (-3,5%) There was news today in the form of a 52-week high.
Corcept Therapeutics Incorporated’s stock reached a new 52-week high of $91.1, marking an important milestone. Year-to-date, the stock has posted a remarkable gain of 33.53%, while the price has risen 159% since the beginning of the year. As a result, the company’s market capitalization rose to $9.68 billion. According to an analysis by InvestingPro, the stock is currently trading above its fair value and is therefore considered overvalued. An InvestingPro tip also indicates that the RSI suggests the stock is overbought. This 52-week high underscores Corcept Therapeutics’ current performance and market position.
In other recent news, Corcept Therapeutics has resubmitted its New Drug Application (NDA) for Relacorilant to treat Cushing’s syndrome to the U.S. Food and Drug Administration (FDA). The resubmission includes additional analyses required by the FDA. The company expects a six-month review period. In its financial results for the first quarter of 2026, Corcept reported total revenue of approximately $165 million, which was below the consensus estimate of $186 million. Following the release of these figures, H.C. Wainwright raised its price target for Corcept stock from $65 to $75 and maintained its “Buy” rating.
In addition, Corcept presented promising data from its Phase 3 ROSELLA trial at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated Lifyorli (relacorilant) in combination with Nab-paclitaxel for the treatment of platinum-resistant ovarian cancer. The results showed a 35% reduction in the risk of death compared to Nab-paclitaxel alone. Based on the presented analyses of overall survival in the subgroups, H.C. Wainwright reaffirmed its “Buy” rating and a price target of $95. Corcept’s ongoing efforts in the treatment of Cushing’s syndrome and ovarian cancer underscore the company’s significant progress.
